A businessman in Sussex watched £14,244 drain out of his Metro Bank account. The money went on credits for Claude, the AI chatbot he already paid to use. Two things failed at once. Criminals had turned a chatbot into a way to cash out stolen cards. And…
Britain tried to force a backdoor into Apple’s encryption last year and lost. It has not given up. It has narrowed the demand, served it again, and Apple is back in a secret court to fight it. Apple has filed a fresh challenge at the Investigatory Powe…
Apple has appealed a new legal demand by the U.K. government, which critics say could threaten the privacy rights of users all over the world.
A London startup building the training grounds for Europe’s autonomous weapons has come out of stealth with $30mn. It is one of the region’s largest defence-tech seed rounds this year. Agon is not building the weapons themselves. It is building the inf…
NHS England has admitted that a key data-protection document misstated who could see patients’ medical records. It did not disclose the whole arrangement. Staff at Palantir, the US data-analytics firm, can view identifiable patient data inside part of …
Steven Bartlett has built one of the world’s biggest podcasts on the idea that the right people, obsessively managed, make the machine. Now four of those people have walked out the door. The star host of “The Diary of a CEO” has lost four core staffers…
Nscale, the London AI-cloud company that owns its own power and data centres, is buying its way up the stack. It has agreed to acquire Anyscale, the startup behind the widely used Ray software. Bloomberg reported the deal at about $1.65bn. Nscale annou…
London-based Inforcer just closed a $50 million Series C round led by Insight Partners.
The race to build an AI “foundation model of the cell” has a fuel problem. The biological data needed to train one is scarce, messy and inconsistent. Relation Therapeutics thinks the answer is to manufacture that data itself, and GSK is paying up to $1…
Most AI imaging startups build one model per disease. A Cambridge company has raised $20m to build a single model for the whole chest. Then it can spin the rest out of that. Qureight makes AI imaging tools for lung and heart clinical trials. It closed …